{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:11:07Z","timestamp":1794568267551,"version":"4.9.1"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004250","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000}}],"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116019"],"award-info":[{"award-number":["116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116019"],"award-info":[{"award-number":["116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116019"],"award-info":[{"award-number":["116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116019"],"award-info":[{"award-number":["116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116019"],"award-info":[{"award-number":["116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001491","name":"Belgian American Educational Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) infections are among the primary causes of death for children under 5 years of age worldwide. A notable challenge with many of the upcoming prophylactic interventions against RSV is their short duration of protection, making the age profile of key interest to the design of prevention strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We leverage the RSV data collected on cases, hospitalizations, and deaths in a systematic review in combination with flexible generalized additive mixed models (GAMMs) to characterize the age burden of RSV incidence, hospitalization, and hospital-based case fatality rate (hCFR). Due to the flexible nature of GAMMs, we estimate the peak, median, and mean incidence of infection to inform discussions on the ideal \u201cwindow of protection\u201d of prophylactic interventions. In a secondary analysis, we reestimate the burden of RSV in all low- and middle-income countries. The peak age of community-based incidence is 4.8 months, and the mean and median age of infection is 18.9 and 14.7 months, respectively. Estimating the age profile using the incidence coming from hospital-based studies yields a slightly younger age profile, in which the peak age of infection is 2.6 months and the mean and median age of infection are 15.8 and 11.6 months, respectively. More severe outcomes, such as hospitalization and in-hospital death have a younger age profile. Children under 6 months of age constitute 10% of the population under 5 years of age but bear 20% to 29% of cases, 28% to 39% of hospitalizations, and 38% to 50% of deaths.<\/jats:p>\n                    <jats:p>On an average year, we estimate 28.23 to 31.34 million cases of RSV, between 2.95 to 3.35 million hospitalizations, and 16,835 to 19,909 in-hospital deaths in low, lower- and upper middle-income countries. In addition, we estimate 17,254 to 23,875 deaths in the community, for a total of 34,114 to 46,485 deaths. Globally, evidence shows that community-based incidence may differ by World Bank Income Group, but not hospital-based incidence, probability of hospitalization, or the probability of in-hospital death (p \u2264 0.01, p = 1, p = 0.86, 0.63, respectively). Our study is limited mainly due to the sparsity of the data, especially for low-income countries (LICs). The lack of information for some populations makes detecting heterogeneity between income groups difficult, and differences in access to care may impact the reported burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We have demonstrated an approach to synthesize information on RSV outcomes in a statistically principled manner, and we estimate that the age profile of RSV burden depends on whether information on incidence is collected in hospitals or in the community. Our results suggest that the ideal prophylactic strategy may require multiple products to avert the risk among preschool children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004250","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T13:35:06Z","timestamp":1689600906000},"page":"e1004250","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: A semi-parametric, meta-regression approach"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-6030","authenticated-orcid":true,"given":"Marina","family":"Antill\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-1791","authenticated-orcid":true,"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-1196","authenticated-orcid":true,"given":"Lander","family":"Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-5291","authenticated-orcid":true,"given":"Joke","family":"Bilcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"RESCEU investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":true,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5034-3595","authenticated-orcid":true,"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"pmed.1004250.ref001","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-med-051214-024241","article-title":"New vaccines for the world\u2019s poorest people.","volume":"67","author":"PJ Hotez","year":"2016","journal-title":"Annu Rev Med"},{"issue":"10200","key":"pmed.1004250.ref002","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(19)30721-4","article-title":"Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study","volume":"394","author":"KL O\u2019Brien","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"pmed.1004250.ref003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pone.0008088","article-title":"The level and duration of RSV-specific maternal IgG in infants in Kilifi, Kenya.","volume":"4","author":"R Ochola","year":"2009","journal-title":"PLoS ONE"},{"issue":"15","key":"pmed.1004250.ref004","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.vaccine.2015.02.039","article-title":"Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya","volume":"33","author":"JU Nyiro","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"pmed.1004250.ref005","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/infdis\/jiu316","article-title":"Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh","volume":"210","author":"HY Chu","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"pmed.1004250.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01802-8","article-title":"Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis","volume":"18","author":"D Hodgson","year":"2020","journal-title":"BMC Med"},{"key":"pmed.1004250.ref007","article-title":"Contact With Young Children Increases the Risk of Respiratory Infection in Older Adults in Europe\u2014the RESCEU Study","author":"K Korsten","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"pmed.1004250.ref008","doi-asserted-by":"crossref","first-page":"0381","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases.","volume":"5","author":"J Mossong","year":"2008","journal-title":"PLoS Med"},{"issue":"10","key":"pmed.1004250.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0076180","article-title":"The Social Life of Infants in the Context of Infectious Disease Transmission; Social Contacts and Mixing Patterns of the Very Young.","volume":"8","author":"AJ van Hoek","year":"2013","journal-title":"PLoS ONE."},{"key":"pmed.1004250.ref010","first-page":"10","article-title":"Social contact patterns and implications for infectious disease transmission: A systematic review and meta-analysis of contact surveys.","author":"A Mousa","year":"2021","journal-title":"Elife"},{"issue":"37","key":"pmed.1004250.ref011","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1016\/j.vaccine.2014.05.038","article-title":"The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants","volume":"32","author":"CJ Sande","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"pmed.1004250.ref012","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/aje\/kws257","article-title":"The natural history of respiratory syncytial virus in a birth cohort: The influence of age and previous infection on reinfection and disease","volume":"176","author":"EO Ohuma","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pmed.1004250.ref013","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"CB Hall","year":"1991","journal-title":"J Infect Dis"},{"key":"pmed.1004250.ref014","first-page":"600","article-title":"The new wave of vaccines for a killer respiratory virus","author":"K. Powell","year":"2020","journal-title":"Nature"},{"issue":"5","key":"pmed.1004250.ref015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants","volume":"383","author":"SA Madhi","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1004250.ref016","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/AAC.43.5.1183","article-title":"Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.","volume":"43","author":"HC Meissner","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"pmed.1004250.ref017","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","article-title":"Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection","volume":"13","author":"B. Resch","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"pmed.1004250.ref018","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.","volume":"37","author":"JB Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J."},{"issue":"9","key":"pmed.1004250.ref019","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"LL Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"S1","key":"pmed.1004250.ref020","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jped.2022.10.004","article-title":"Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood","volume":"99","author":"M Comerlato Scotta","year":"2023","journal-title":"J Pediatr (Rio J)"},{"issue":"1","key":"pmed.1004250.ref021","first-page":"1","article-title":"Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.","volume":"18","author":"X Li","year":"2020","journal-title":"BMC Med."},{"issue":"33","key":"pmed.1004250.ref022","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1016\/j.vaccine.2020.06.036","article-title":"The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models","volume":"38","author":"R Baral","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"pmed.1004250.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2020-046563","article-title":"Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.","volume":"11","author":"R Baral","year":"2021","journal-title":"BMJ Open"},{"issue":"35","key":"pmed.1004250.ref024","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2021.06.086","article-title":"Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions","volume":"39","author":"RS Laufer","year":"2021","journal-title":"Vaccine"},{"issue":"9","key":"pmed.1004250.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0163567","article-title":"Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on bursa data.","volume":"11","author":"KB Pouwels","year":"2016","journal-title":"PLoS ONE."},{"issue":"1","key":"pmed.1004250.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0283-x","article-title":"Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.","volume":"13","author":"P Poletti","year":"2015","journal-title":"BMC Med"},{"issue":"4","key":"pmed.1004250.ref027","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/cid\/ciu327","article-title":"Maternal immunization.","volume":"59","author":"HY Chu","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pmed.1004250.ref028","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jama.2021.23772","article-title":"RSV Vaccines, Finally Within Reach, Could Prevent Tens of Thousands of Yearly Deaths","volume":"327","author":"J. Abbasi","year":"2022","journal-title":"JAMA"},{"key":"pmed.1004250.ref029","first-page":"16","author":"World Health Organisation. Characteristics for Respiratory Syncytial Virus (RSV) Vaccines","year":"2017","journal-title":"Department of Immunization, Vaccines and Biologicals"},{"issue":"10098","key":"pmed.1004250.ref030","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"T Shi","year":"2017","journal-title":"Lancet"},{"key":"pmed.1004250.ref031","first-page":"1","article-title":"Study Group in Lyon, Respiratory Virus Global Epidemiology Network, RESCEU. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2019: a systematic analysis","author":"VRS Li Y","year":"2022","journal-title":"SSRN preprint."},{"issue":"9725","key":"pmed.1004250.ref032","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"H Nair","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"pmed.1004250.ref033","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"C Troeger","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"pmed.1004250.ref034","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1016\/S2214-109X(17)30344-3","article-title":"Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.","volume":"5","author":"NM Scheltema","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"5","key":"pmed.1004250.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0177803","article-title":"Defining the vaccination window for Respiratory syncytial virus (RSV) using ageseroprevalence data for children in Kilifi, Kenya.","volume":"12","author":"JU Nyiro","year":"2017","journal-title":"PLoS ONE"},{"key":"pmed.1004250.ref036","doi-asserted-by":"crossref","DOI":"10.1201\/9781315370279","volume-title":"Generalized Additive Models","author":"SN Wood","year":"2017"},{"key":"pmed.1004250.ref037","volume-title":"Springer Texts in Statistics","author":"G James","year":"2013"},{"key":"pmed.1004250.ref038","volume-title":"Integrated Management of Childhood Illness (IMCI): Chart Booklet. March","author":"World Health Organization","year":"2014"},{"key":"pmed.1004250.ref039","volume-title":"Integrated Management of Childhood Illness: management of the sick young infant aged up to 2 months","author":"World Health Organization","year":"2019"},{"key":"pmed.1004250.ref040","volume-title":"An Integrative Metaregression Framework for Descriptive Epidemiology","author":"AD Flaxman","year":"2015"},{"key":"pmed.1004250.ref041","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1093\/cid\/ciab528","article-title":"Global Respiratory Syncytial Virus-Related Infant Community Deaths","volume":"73","author":"NI Mazur","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pmed.1004250.ref042","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4269\/ajtmh.17-0586","article-title":"Perspective piece rotavirus vaccine will improve child survival by more than just preventing diarrhea: Evidence from Bangladesh","volume":"98","author":"S Saha","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"pmed.1004250.ref043","first-page":"1995","article-title":"Global regional and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in","author":"H Nair","year":"2015"},{"key":"pmed.1004250.ref044","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2019: a systematic analysis, 2017\u20132020 [dataset]","author":"Y Li","year":"2021"},{"issue":"26","key":"pmed.1004250.ref045","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1002\/sim.9159","article-title":"A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data.","volume":"40","author":"MT Phillips","year":"2021","journal-title":"Stat Med"},{"issue":"10","key":"pmed.1004250.ref046","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41577-022-00764-7","article-title":"Respiratory syncytial virus after the SARS-CoV-2 pandemic\u2014what next","volume":"22","author":"LG Mosscrop","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"pmed.1004250.ref047","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1002\/jmv.28065","article-title":"A delayed resurgence of respiratory syncytial virus (RSV) during the COVID-19 pandemic: An unpredictable outbreak in a small proportion of children in the Southwest of Iran, April 2022.","volume":"94","author":"L Mohebi","year":"2022","journal-title":"J Med Virol"},{"issue":"5","key":"pmed.1004250.ref048","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/irv.12998","article-title":"International changes in respiratory syncytial virus (RSV) epidemiology during the COVID-19 pandemic: Association with school closures.","volume":"16","author":"MN Billard","year":"2022","journal-title":"Influenza Other Respi Viruses"},{"key":"pmed.1004250.ref049","article-title":"Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate.","author":"Pfizer, Inc","year":"2022"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004250","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T13:35:41Z","timestamp":1690810541000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.g004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.g005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.g006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.g007","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.s004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.s005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.s006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.r001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.r002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.r003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.r004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.r005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004250.r006","asserted-by":"subject"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}